Inspra (Eplerenone)

Eplerenone selectively blocks aldosterone receptors in the distal tubules of the kidney. By preventing aldosterone from promoting sodium reabsorption and potassium excretion, it encourages sodium loss, modest diuresis, and potassium retention, which together lower blood pressure and lessen cardiac workload.

The specific dose of Inspra is determined by the prescribing clinician based on the individual’s medical condition, renal function, and potassium levels. Dosage adjustments are made according to therapeutic response and laboratory monitoring.

Inspra is classified as Pregnancy Category B, indicating no evidence of fetal risk in animal studies, but adequate human data are lacking. It should be used during pregnancy only if clearly needed. Breastfeeding is not recommended without medical advice, as eplerenone may pass into milk.

To order Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inspra (eplerenone) is more selective for the mineralocorticoid receptor than spironolactone, resulting in fewer anti‑androgenic side effects such as gynecomastia. However, both agents share similar efficacy in lowering blood pressure and improving heart‑failure outcomes, with dosing and monitoring requirements that are comparable.

Inspra tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and store out of reach of children.

Inspra is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most serious risks include severe hyperkalaemia, which can cause cardiac arrhythmias, and acute renal failure. Patients should be monitored for sudden drops in blood pressure, signs of angioedema, and liver function abnormalities.

Inspra is contraindicated in patients with known hypersensitivity to eplerenone, those with serum potassium levels above 5.0 mmol/L, severe renal impairment (eGFR <30 mL/min/1.73 m²), and in individuals with significant hepatic dysfunction. It should also be avoided in patients taking other potassium‑sparing agents without careful monitoring.